- ROUNDTABLE: Improving patient outcomes, controlling costs with OTCs
- Teva launches authorized generic version of Pfizer's Detrol LA
- Generic drug prices spike, but PBMs' reimbursement rates don't keep up, NCPA study finds
- Study: 2,000 IUs of vitamin E daily effective in slowing functional decline in AD patients
- 21 health industry groups address FDA on proposed changes to generic drug label rules
PEAPACK, N.J. The generics division of Pfizer will sell an authorized generic version of a drug used to treat dementia.
Greenstone said Wednesday that it had agreed with Eisai to launch donepezil hydrochloride tablets, an authorized generic of Aricept. The drug is used to treat dementia related to Alzheimer’s disease. Eisai makes the drug under a partnership with Pfizer.
“We are excited about the opportunity to work with Eisai to introduce this important authorized generic to patients,” said James Cannon, Greenstone’s VP business alliances. “First and foremost, our goal is to provide donepezil hydrochloride tablets to the broad customer base, and we also strive to remain competitive with other potential generic versions of the product.”
Unlike generic drugs, which are marketed in competition with their branded counterparts and must undergo an abbreviated regulatory approval process through the Food and Drug Administration, authorized generics are essentially branded drugs marketed under their generic names with the authorization of the original drug’s manufacturer and often through third-party companies.